CAMBRIDGE, Mass. & SALISBURY, England – KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has shared insights from U.S. patient surveys at the American Academy of Allergy, Asthma & Immunology Annual Meeting, revealing the struggles faced by patients with Hereditary Angioedema (HAE) using injectable on-demand treatments. The surveys, presented in Washington, DC, highlighted issues such as treatment delays, anxiety, and non-compliance with treatment guidelines.
The research indicated that patients who delayed on-demand treatment experienced longer attack durations and heightened anxiety, regardless of whether they also used long-term prophylaxis (LTP).
Patients often hesitated to treat attacks promptly due to uncertainty about the attack's severity or concerns about treatment availability. Notably, nearly one-third of patients using icatibant, an injectable medication, delayed or did not treat attacks out of anxiety about refilling prescriptions.
The findings also revealed that early treatment, within one hour of an attack, led to quicker recovery and fewer instances of attacks returning. However, barriers such as the embarrassment of carrying injectable treatments and the desire to save medication for severe attacks contributed to delays.
KalVista's CEO, Andrew Crockett, emphasized the importance of addressing these unmet needs and expressed optimism about the potential of sebetralstat, their oral on-demand therapy. Positive phase 3 trial data for sebetralstat was disclosed earlier in February 2024, and the company plans to submit a new drug application to the U.S. FDA in the first half of 2024, with subsequent filings in Europe and Japan.
KalVista is developing oral small molecule protease inhibitors, including an oral Factor XIIa inhibitor program, which may offer improved treatment options for HAE and other conditions. The company's commitment to advancing HAE treatments is part of its broader focus on addressing diseases with significant unmet medical needs.
This report is based on a press release statement from KalVista Pharmaceuticals, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.